Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of cancer"
DOI: 10.1016/j.ejca.2021.01.010
Abstract: BACKGROUND In the EORTC 1410/INTELLANCE 2 randomised, phase II study (NCT02343406), with the antibody-drug conjugate depatuxizumab mafodotin (Depatux-M, ABT-414) in patients with recurrent EGFR-amplified glioblastoma, the primary end-point (overall survival) was not met, and the… read more here.
Keywords: egfr amplified; glioblastoma; depatux; health ... See more keywords
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.
Sign Up to like & getrecommendations! Published in 2021 at "Neuro-oncology"
DOI: 10.1093/neuonc/noab133
Abstract: BACKGROUND Antibody drug conjugates (ADCs) targeting the epidermal growth factor receptor (EGFR), such as depatuxizumab mafodotin (Depatux-M), is a promising therapeutic strategy for glioblastoma (GBM) but recent clinical trials did not demonstrate a survival benefit.… read more here.
Keywords: egfr; delivery; depatux; drug ... See more keywords